HR Execs on the Move

Sisters of Saint Joseph of Philadelphia

www.ssjphila.org

 
We are a community of approximately 825 women religious. Originally founded in 1650 in LePuy, France, the Sisters of Saint Joseph came to Philadelphia in 1847. Through our many ministries, including educations, healthcare, social services and parish m...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ssjphila.org
  • 9701, Germantown Avenue
    Philadelphia, PA USA 19118
  • Phone: 215.248.7228

Executives

Name Title Contact Details

Similar Companies

TCGRx

TCG employs a team of pharmacy designers and industrial engineers who can help with the integration of automation or storage and retrieval solutions that will meet the business needs of the pharmacy.

Rondo-Pak

Rondo-Pak is a global print and packaging specialist providing effective solutions and comprehensive services to the pharmaceutical and life sciences industries. The company`s portfolio of sophisticated packaging solutions addresses precise requirements for compliance, child resistance, anti-counterfeiting e-pedigree and more. Rondo-Pak has been a recognized leader in pharmaceutical folding cartons for over 70 years, and is a proud part of the Körber Medipak network of companies.

CORIA Laboratories

CORIA Laboratories, Ltd. is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BlueSprig

Our mission is simple: we are focused on changing the world for children with autism. Learn more about our ABA Services.

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).